Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $491.34 --0%
Revenue Growth %: +8.4%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +8.4%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.47, $0.14 better than the analyst estimate of $4.33. Revenue for the quarter came in at $2.99 billion versus the consensus estimate of $3.03 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of $13.05 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MetLife estimates Q2 2026 variable investment income below annual pace
- Diana Shipping extends Genco tender offer deadline to July 10
- Increasing unusual call option volume: ROL QSR ERAS TEL TENB WEN PPL SIG
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
